montelukast and Postoperative-Complications

montelukast has been researched along with Postoperative-Complications* in 4 studies

Trials

1 trial(s) available for montelukast and Postoperative-Complications

ArticleYear
Role of leukotriene inhibitors in the postoperative management of nasal polyps.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2005, Volume: 67, Issue:3

    This was a prospective double blind comparative study on 40 patients. It compared the effects of the leukotriene receptor antagonist montelukast and beclomethasone nasal spray on the post-operative course of patients with sinonasal polyps. All patients underwent endoscopic sphenoethmoidectomy and were randomized post-operatively into two groups. Group I: 20 patients (9 females and 11 males) age 17 to 67 (32.4 +/- 9.5 years), receiving 10 mg montelukast orally daily and Group II: 20 patients (6 females and 14 males) age 17 years to 57 years (33.5 +/- 11.9 years), receiving 400 ug beclomethasone local sprays daily. All patients were followed up for 1 year and a symptom score was recorded throughout this period. There was a significant reduction in symptom scores in both groups throughout the study period. In the montelukast group improvement was more marked in itching, post-nasal discharge and headache. The control of sneezing and rhinorrhea was comparable in both groups with a marginal advantage of montelukast. Steroids had a more marked effect on smell disturbances and obstruction. There was no difference in the recurrence rate or in the need for rescue medications between both groups. Both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.

    Topics: Acetates; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Beclomethasone; Chi-Square Distribution; Cyclopropanes; Double-Blind Method; Female; Glucocorticoids; Headache; Humans; Leukotriene Antagonists; Male; Middle Aged; Nasal Polyps; Olfaction Disorders; Postoperative Care; Postoperative Complications; Prospective Studies; Pruritus; Quinolines; Sneezing; Sulfides

2005

Other Studies

3 other study(ies) available for montelukast and Postoperative-Complications

ArticleYear
Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis.
    International forum of allergy & rhinology, 2016, Volume: 6, Issue:3

    Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes.. Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty-item Sino-Nasal Outcomes Test (SNOT-20) scores and Lund-Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications.. Fifty-two therapy lapses were identified in 50 patients. Twenty-seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow-up was 46.5 months. Overall, SNOT-20 scores and endoscopy scores were significantly lower with montelukast (p < 0.005 for both). On subgroup analysis, SNOT-20 scores were significantly improved for patients with eCRSwNP and AFS (p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP (p = 0.044). Outcomes approached, but did not reach, significance for patients with ST (p = 0.123 for SNOT-20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma.. The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.

    Topics: Acetates; Adolescent; Adult; Aged; Asthma; Chronic Disease; Cyclopropanes; Eosinophils; Female; Follow-Up Studies; Humans; Leukotriene Antagonists; Male; Middle Aged; Postoperative Complications; Quinolines; Retrospective Studies; Rhinitis; Rhinoplasty; Sinusitis; Sulfides; Treatment Outcome; Young Adult

2016
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.
    Annals of the American Thoracic Society, 2016, Volume: 13, Issue:11

    The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies.. To describe the longitudinal trajectory of lung function parameters, including FEV. Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV. The FEV

    Topics: Acetates; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azithromycin; Bronchiolitis Obliterans; Cyclopropanes; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Linear Models; Lung; Male; Middle Aged; Multivariate Analysis; Postoperative Complications; Prospective Studies; Quinolines; Retrospective Studies; Sulfides; Survival Rate; United States; Young Adult

2016
The effect of montelukast and antiadhesion barrier solution on the capsule formation after insertion of silicone implants in a white rat model.
    European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2013, Volume: 51, Issue:3-4

    Capsular contracture is one of the most severe complications that can occur in breast surgery following silicone implant insertion. The purpose of this study was to investigate the effect of montelukast and antiadhesion barrier solution (AABS) on reducing capsular formation and their possible synergism.. This study was approved by the Animal Ethics Committee (Reference No. KNU 2012-33) and was conducted in accordance with the Kyungpook National University - Institutional Animal Care and Use Committee, Animal Ethics Committee. The experiments in this study were conducted in vivo in 4 groups of 24 rats. Following silicone implant insertion, the pocket was injected with different agents. Group I (control group) was given normal saline injections into the pocket and fed with pure water. Group II was given injections of AABS and fed with pure water. Group III was given injections of normal saline and the medication montelukast during the experimental period. Group IV was given injections of AABS and montelukast as postoperative medication. Peri-implant capsules were excised after 8 weeks and were evaluated for transparency, inflammatory cell content, capsule thickness, collagen pattern and TGF-β expression.. The capsules in the experimental groups (i.e., groups II-IV) were significantly more transparent than those in group I (controls; p < 0.05, Student's t test). The mean capsule thickness of the experimental groups II (296 ± 14.76 μm), III (280 ± 14.77 μm) and IV (276 ± 39.28 μm) was smaller than that of the control group I (361 ± 35.43 μm). Compared to the control group, the histologic findings in the experimental groups suggested a decreased inflammatory response occurring in the peri-implant capsules as they exhibited minor vascularization and a reduced number of mast cells and macrophages. The collagen patterns in the experimental groups were of a lower density than in the control group with the former showing a loose, tidy collagen pattern. The amounts of TGF-β and collagen I were higher in the control group than in the experimental groups. Group IV (the synergic effect group) had a more pronounced effect on all the parameters examined than that in groups II and III with separate drug administration.. Montelukast and AABS reduced the thickness, the inflammatory cell infiltrate and the myofibroblast content of the peri-implant capsules around silicone implants in this white rat model. They lowered the expression of the fibrotic mediator, TGF-β, and inhibited the peri-implant capsular fibrosis. Therefore, montelukast and AABS are effective in the reduction of silicone-induced peri-implant capsular formation.

    Topics: Acetates; Animals; Breast Implants; Collagen; Cyclopropanes; Immunohistochemistry; Postoperative Complications; Quinolines; Rats; Rats, Sprague-Dawley; Silicones; Solutions; Sulfides; Transforming Growth Factor beta

2013